Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
ADALIMUMAB (UNII: FYS6T7F842) (ADALIMUMAB - UNII:FYS6T7F842)
A-S Medication Solutions
PRESCRIPTION DRUG
HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate. HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs. HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. HUMIRA is indicated for the treatment of moderately to seve
HUMIRA® (adalimumab) is supplied as a preservative-free, sterile, clear and colorless solution for subcutaneous administration. The following packaging configurations are available. Storage and Stability Do not use beyond the expiration date on the container. HUMIRA must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen even if it has been thawed. Store in original carton until time of administration to protect from light. If needed, for example when traveling, HUMIRA may be stored at room temperature up to a maximum of 77°F (25°C) for a period of up to 14 days, with protection from light. HUMIRA should be discarded if not used within the 14-day period. Record the date when HUMIRA is first removed from the refrigerator in the spaces provided on the carton and dose tray. Do not store HUMIRA in extreme heat or cold.
Biologic Licensing Application
A-S Medication Solutions ---------- MEDICATION GUIDE HUMIRA® (Hu-MARE-ah) (adalimumab) injection, for subcutaneous use Read the Medication Guide that comes with HUMIRA before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. What is the most important information I should know about HUMIRA? HUMIRA is a medicine that affects your immune system. HUMIRA can lower the ability of your immune system to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi or bacteria that have spread throughout the body. Some people have died from these infections. • Your doctor should test you for TB before starting HUMIRA. • Your doctor should check you closely for signs and symptoms of TB during treatment with HUMIRA. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay. Before starting HUMIRA, tell your doctor if you: • think you have an infection or have symptoms of an infection such as: • fever, sweats, or chills • muscle aches • cough • shortness of breath • blood in phlegm • warm, red, or painful skin or sores on your body • diarrhea or stomach pain • burning when you urinate or urinate more often than normal • feel very tired • weight loss • are being treated for an infection. • get a lot of infections or have infections that keep coming back. • have diabetes. • have TB, or have been in close contact with someone with TB. • were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your doctor if you are not sure. • live or have lived in certain parts of the country (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis). read_full_document
HUMIRA- ADALIMUMAB A-S MEDICATION SOLUTIONS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE HUMIRA SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR HUMIRA. HUMIRA (ADALIMUMAB) INJECTION, FOR SUBCUTANEOUS USE INITIAL U.S. APPROVAL: 2002 WARNING: SERIOUS INFECTIONS AND MALIGNANCY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ SERIOUS INFECTIONS (5.1, 6.1): INCREASED RISK OF SERIOUS INFECTIONS LEADING TO HOSPITALIZATION OR DEATH, INCLUDING TUBERCULOSIS (TB), BACTERIAL SEPSIS, INVASIVE FUNGAL INFECTIONS (SUCH AS HISTOPLASMOSIS), AND INFECTIONS DUE TO OTHER OPPORTUNISTIC PATHOGENS. DISCONTINUE HUMIRA IF A PATIENT DEVELOPS A SERIOUS INFECTION OR SEPSIS DURING TREATMENT. PERFORM TEST FOR LATENT TB; IF POSITIVE, START TREATMENT FOR TB PRIOR TO STARTING HUMIRA. MONITOR ALL PATIENTS FOR ACTIVE TB DURING TREATMENT, EVEN IF INITIAL LATENT TB TEST IS NEGATIVE. MALIGNANCY (5.2): LYMPHOMA AND OTHER MALIGNANCIES, SOME FATAL, HAVE BEEN REPORTED IN CHILDREN AND ADOLESCENT PATIENTS TREATED WITH TNF BLOCKERS INCLUDING HUMIRA. POST-MARKETING CASES OF HEPATOSPLENIC T-CELL LYMPHOMA (HSTCL), A RARE TYPE OF T- CELL LYMPHOMA, HAVE OCCURRED IN ADOLESCENT AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH TNF BLOCKERS INCLUDING HUMIRA. RECENT MAJOR CHANGES Indications and Usage, Ulcerative Colitis (1.6) 2/2021 Dosage and Administration, Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis (2.1) 12/2020 Dosage and Administration, Ulcerative Colitis (2.4) 2/2021 Dosage and Administration, Hidradenitis Suppurativa (2.6) 12/2020 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: RHEUMATOID ARTHRITIS (RA) (1.1): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. JUVENILE IDIOPATHIC ARTHRITIS (JIA) (1.2): reducing signs and symptoms of moderatel read_full_document